The strategic alliance agreement is for five years between Azopharma and Accu-Break Pharmaceuticals (ABP). Azopharma will provide sales and marketing support for Accu-Break technologies for five years. The Accu-Break tablet technologies, which are US patented until at least 2025 provide solutions for pharmaceutical companies as well as physicians and patients in overcoming issues associated with tablet breaking and dose splitting.
Phil Meeks, CEO of Azopharma, said: “We are excited to be the center of excellence for the development of products using Accu-Break technologies. Our expertise in formulation and in total product development makes us the ideal partner for ABP.”